Journal of Histochemistry and Cytochemistry, Vol. 45, 1307-1314, Copyright © 1997 by The Histochemical Society, Inc.


TECHNICAL NOTE

Detection of the Receptor for the Human Urokinase-type Plasminogen Activator Using Fluoresceinated uPA

Rosalba Ciccocioppoa, Maria G. Capria, and Saverio Albertia
a Laboratory of Experimental Oncology, Department of Cellular Biology and Oncology, Istituto di Ricerche Farmacologiche Mario Negri-Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy

Correspondence to: Saverio Alberti, Institute Mario Negri Sud, 66030 S., Maria Imbaro (Chieti), Italy.


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The urokinase-type plasminogen activator (uPA) is a serine protease that plays a crucial role in blood coagulation and in tumor invasion and metastasis. uPA is a relatively large polypeptide and binds the uPA receptor (uPAR) with high affinity and specificity. Therefore, it was a good candidate for direct labeling with a fluorochrome for detection of the uPAR. We have produced a fluorescein (FITC)-labeled human uPA using a conjugation procedure that did not significantly alter its binding characteristics to the uPAR. Thirty nM FITC-uPA efficiently stains 2 x 105 uPAR-transfected mouse cells in suspension, as determined by flow cytometric analysis. One µg of FITC-uPA efficiently stains 2 x 105 uPAR transfectants grown on slides and analyzed by fluorescence optical microscopy. Human cell lines expressing the endogenous uPAR were stained with similar efficiency. Fixation in paraformaldehyde only slightly reduced the efficiency of staining of both transfectants and cell lines. These characteristics allow the use of FITC-uPA in both static and dynamic morphological studies of uPAR-expressing cells. (J Histochem Cytochem 45:1307-1313, 1997)

Key Words: urokinase-type plasminogen activator, fluorescein labeling, cell surface receptors, fluorescence microscopy, flow cytometry


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The serine protease urokinase-type plasminogen activator (uPA) is synthesized as a soluble single-chain inactive precursor (pro-uPA) and is activated by proteolysis after binding to the uPA receptor (uPAR). Active uPA specifically proteolizes plasminogen into plasmin, which in turn degrades extracellular matrix proteins (fibronectin, laminin, and proteoglycans) or activates matrix metalloproteases and the pro-uPA itself (Mignatti and Rifkin 1993 ). uPA and the uPAR play a crucial role in blood coagulation, participating in the plasma procoagulant and fibrinolytic systems (Simon et al. 1996 ). Moreover, they influence the procoagulant and/or fibrinolytic activity of circulating cells (Simon et al. 1996 ). uPA can also enhance tumor invasive and metastatic properties in vivo. Tumor cells frequently secrete uPA (Danø et al. 1985 ; Hearing et al. 1989 ; Ossowski et al. 1991 ; Pyke et al. 1991 ; Mignatti and Rifkin 1993 ) and highly invasive human carcinomas frequently show high levels of uPA (Duffy et al. 1988 ). The murine melanoma B16-F10 cell line with low metastatic potential can acquire a much greater capacity to form lung colonies in mice when transfected with human uPA (huPA) (Schultz et al. 1992 ). Conversely, the metastatization of different tumor cell lines can be strongly inhibited by anti-uPA antibodies (Mignatti and Rifkin 1993 ; Ossowski et al. 1991 ; Ossowski and Reich 1983 ). A main mechanism of action of the uPA-uPAR complex appears to be the degradation of the extracellular matrix (ECM), which permits malignant cells to migrate away from their original site of growth. Indeed, mouse L-fibroblasts transfected with the uPAR (Mignatti and Rifkin 1993 ) and grown on a reconstituted ECM show proteolytic properties in the presence of uPA and migrate through the ECM. Similarly, when mouse L-cells transfected with the human uPA are co-cultivated with L-cells transfected with the huPAR on chorioallantoic membrane (CAM) or on ECM, functional uPA-uPAR complexes are reconstituted and both types of transfectants invade the substrate (Quax et al. 1991 ; Mignatti and Rifkin 1993 ). Consistent with this mechanism of action, antibodies and inhibitors of uPA activity inhibit both ECM degradation and invasion of either the amniotic membrane or of reconstituted basement membrane (Mignatti and Rifkin 1993 ).

Because uPA, together with other proteases, can play a major role in blood coagulation and tumor invasion, it would be of interest to be able to efficiently follow the uPA-uPAR complex, e. g., during its formation, internalization or shedding, and interaction with its substrate. Of further use would be detection of the uPA-uPAR complex on living cells and following it dynamically over time. To reach this goal, we decided to produce a directly labeled uPA that could be used with high efficiency in fluorescence microscopy and flow cytometry. The huPA has a Kd of 2-20 x 10-9 M for the uPAR (Roldan et al. 1990 ), i. e., it binds uPAR with a similar if not higher affinity than mono- or polyclonal antibodies (Nisonoff et al. 1975 ). The high Kd indicated the feasibility of direct detection of the uPAR using its ligand, as we could expect a similar if not higher efficiency of detection than with antibodies. Moreover, uPA was expected to be more specific than antibodies, because it detects the uPAR binding site with high affinity and species specificity, whereas antibodies commonly recognize a small cluster of residues that might appear by chance in totally unrelated molecules (Bendayan 1995 ).

The feasibility of direct labeling of uPA was also suggested by the efficient and nondestructive labeling of other proteic ligands, e. g., IL-2 (De Jong et al. 1995 ) and other interleukins, G-CSF, GM-CSF, TNF{alpha}, TGFß (British Biotechnology; Oxford, UK), growth hormone (Bentham et al. 1994 ), insulin-like growth factor-I (Bentham et al. 1993 ), EGF (Azevedeo and Johnson 1990 ), and transferrin (Uriel et al. 1990 ). Most proteins are either fluorescein (FITC)- or biotin-conjugated (Hardy 1986 ; Azevedeo and Johnson 1990 ; Uriel et al. 1990 ; Bentham et al. 1993 , Bentham et al. 1994 ; De Jong et al. 1995 ). Biotin conjugation has the theoretical advantage of allowing a flexible use of streptavidin conjugated to different fluorochromes (Parks et al. 1986 ). However, FITC offers the great advantage of direct labeling and visualization of the target molecules with a single incubation step, i. e., more conveniently and with better control of the binding conditions. Therefore, we tested the feasibility of FITC conjugation of uPA. Here we show that uPA can be efficiently labeled with FITC and binds the uPA receptor with high specificity and essentially the same affinity as unlabeled uPA. We prove also that FITC-uPA can efficiently label the uPA receptor on both living and fixed cells and can be used in both flow cytometry and fluorescence microscopy.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Tissue Culture
Murine LB6 cells co-transfected with the phuPAR (containing an expressable human uPAR cDNA) and the pRSVneo selectable vector or with the pRSVneo vector alone (LC) were obtained from Dr. F. Blasi through the courtesy of Dr. P. Mignatti (Roldan et al. 1990 ). HT-1080 and U937 cells were obtained from Drs. A. De Blasi and A. Poggi. The cells were cultured in DMEM or RPMI (Gibco BRL; Paisley, UK) supplemented with 1 g/liter glucose, sodium pyruvate, gluta-mine, penicillin, streptomycin, 10% fetal calf serum (HyClone Laboratories; Logan, UT) (culture medium). Culture medium for transfected cells included 200 µg/ml of geneticin (Sigma Chemical; St Louis, MO) as selecting agent. All cells were maintained in a 5% CO2 incubator at 37C.

FITC Conjugation of uPA
Purified mature, i. e., double-chain human uPA (Ukidan; Serono, Rome, Italy) was kindly supplied through the courtesy of Dr. B. Donati. uPA 400 µg in 0.5 ml PBS were salt-exchanged to carbonate buffer (1.7 g Na2CO3 and 2.8 g NaHCO3 in 100 ml H2O), pH 9.4, using a PD-10 column (Pharmacia; Uppsala, Sweden). FITC freshly dissolved in DMSO was added to uPA in bicarbonate buffer at 27 µg/ml per mg of protein. The FITC-uPA was incubated in the dark under continuous rocking for 3 hr at room temperature (RT). Free FITC was removed from the FITC-uPA containing solution by salt-exchanging on a PD-10 column (Pharmacia). The absorbance of FITC-uPA was measured at 280 nm and 495 nm to determine the fluorochrome to protein (F/P) ratio, using the following formula (Hardy 1986 ):

F = OD495nm/68,000 (FITC molar extinction coefficient)
P = [OD280nm - 31% OD495nm]/0.96 (uPA molar extinction coefficient) x 51,800 (uPA MW)

The molar extinction coefficient of uPA was determined from the absorbance of known amounts of purified uPA in PBS at 280 nm.

FITC-uPA Binding Assay in Flow Cytometry
Cells were collected with PBS 0.6 µM EDTA, centrifuged for 5 min at 1200 RPM at 4C, and resuspended in staining medium (SM). SM is 50% 1 x PBS, 50% 1 x HBSS, 20 mM HEPES, pH 8.1, supplemented with essential and nonessential amino acids, sodium pyruvate (Gibco BRL), 3% fetal calf serum (HyClone), and 0.1% NaN3. Preliminary assays allowed to determine conditions of staining that resulted in high signal on uPAR-expressing cells and no background on control cells (Dell’Arciprete et al. 1996 ) (see Results). Efficient staining was achieved when 2 x 105 cells were incubated for 1 hr on ice with 0.3 µg FITC-uPA in 200 µl of SM, i. e., in 28.9 nM uPA final concentration. After three washes with SM the cells were resuspended in 200 µl of SM with 0.5 µg/ml propidium iodide (SM-PI) and analyzed by flow cytometry. For assays on fixed cells, collected cells were resuspended in 1% paraformaldehyde (PFA) (Sigma Chemical) in PBS and incubated for 10 min on ice. Residual PFA was quenched with 50 mM NH4Cl in PBS for 10 min on ice. After washing, the fixed cells were resuspended in SM without PI.

uPAR Competition Assay in Flow Cytometry
The binding specificity and affinity of FITC-uPA were assayed in a competition assay using unlabeled huPA. Briefly, 0.3 µg of uPA conjugated to FITC was mixed with increasing amounts of unlabeled uPA, i. e., 0.3 µg, 2.7 µg or 29.7 µg. Each premixed solution was added to 2 x 105 living or fixed cells in 200 µl of SM and incubated for 1 hr on ice. After three washes with SM they were resuspended in 200 µl of SM-PI or SM, respectively, and analyzed by flow cytometry. The CV and net fluorescence values of the profiles obtained were compared with the expected values assuming unchanged affinity of uPA after FITC conjugation (see below).

Fluorescence Analysis and Cell Sorting
Fluorescence analysis was performed on a FACSTAR (Becton Dickinson; Sunnyvale, CA), used essentially as described (Parks et al. 1986 ). Calibration of the sorter was performed before each experiment using fluorescent beads. Linearity of the response of the flow cytometer log. amplifiers over four decades was routinely checked, to ensure reproducible quantitation of the results obtained. The figures present log. fluorescence profiles of 5000 cells. Subtraction of cell auto-fluorescence (Alberti et al. 1987 ) and fluorescence overcompensation in the red channel were performed as described (Alberti et al. 1991 ). Forward scatter, side scatter, and propidium iodide gating were routinely used to eliminate dead cells and debris from the analysis. We found it useful to compare different experimental groups by their net fluorescence (Dell’Arciprete et al. 1996 ). We defined the net fluorescence of transfected cells, expressed in arbitrary units (AU), as

arithmetic mean fluorescence of the stained uPAR transfected cells - arithmetic mean fluorescence of the stained pRSVneo transfected control cells

The net fluorescence is an indicator of the total amount of uPA bound to the cells. Importantly, it does not depend on a specific procedure for estimating positive cells and includes dimly expressing cells. The net fluorescence values presented in Table 1 were calculated on 5000 cells.


 
View this table:
[in this window]
[in a new window]
 
Table 1. Competition assay between FITC-uPA and unlabeled uPAa

Fluorescence Microscopy
Two hundred thousand cells were plated on 20 x 20-mm glass coverslips in 6-well tissue culture plates. The next day the coverslips were washed twice in SM and the cells were incubated for 1 hr on ice with 1 µg of FITC-uPA in 50 µl SM. In competition assays, cells were stained with 1 µg of FITC-uPA together with either 1 µg, 9 µg, or 99 µg of unlabeled uPA. Stained coverslips were washed in SM and fixed in the dark for 10 min at RT in 4% paraformaldehyde (PFA) (Sigma Chemical) in PBS. Unreacted PFA was quenched with 50 mM NH4Cl for 10 min at RT. After two washes with SM the coverslips were mounted in Mowiol (Calbiochem-Novabiochem; La Jolla, CA) or in 90% glycerol-10% PBS, and were observed with a Zeiss Axiophot fluorescence microscope.


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

To reduce the chances of inactivating the binding region of uPA for uPAR, uPA was conjugated with FITC using a mild procedure adapted from a FITC conjugation protocol for antibody molecules (Hardy 1986 ). Preliminary tests defined the optimal concentration of FITC and ratio with uPA to obtain a one-to-one ratio of FITC to uPA (F/P). The largest batch of FITC-uPA that was used throughout this work was labeled with 27 µg FITC/ml/mg of protein and possessed an F/P ratio of 0.82.

The binding affinity and specificity of FITC-uPA towards the uPAR was assessed on mouse L-cells transfected with the human uPAR. Quantitation of binding was performed by flow cytometry. The Kd of uPA for uPAR transfectant LB6 cells is about 2-20 x 10-9 M (Appella et al. 1987 ). Therefore, nanomolar concentrations of uPA were predicted to be adequate for transfectant staining. Titration assays were performed by flow cytometry. We used amounts of FITC-uPA corresponding to 2.89 nM, 28.9 nM, and 100 nM for 1 hr on ice. Twenty-nine nM uPA for 1 hr on ice stained 2 x 105 uPAR- transfected LB6 cells to levels essentially identical to 100 nM, i. e., to levels close to saturation. No staining was detectable on LC cells transfected with the pRSVneo vector alone or on untransfected cells incubated with FITC-uPA up to 100 nM (Figure 1A; and data not shown). The essential lack of staining of mouse cells that do express the mouse uPAR (Møller 1993 ) confirmed the species specificity of uPA binding to uPAR (Møller 1993 ). The relative binding affinity of FITC-uPA was assessed in a competition assay with unlabeled uPA. uPAR-transfected or control LC living cells were stained with different ratios of FITC-uPA/unlabeled uPA, i.e., adding no unlabeled uPA or an equal amount or 9-99 fold higher amounts (Table 1). If the affinity of uPA remained constant after labeling with FITC, the reduction in the net cell fluorescence was expected to be proportional to the amount of unlabeled uPA added. Indeed, an equal amount of unlabeled uPA reduced FITC-uPA binding to living cells by 45% vs the expected 50%. Analogously, a 9-fold or a 99-fold higher unlabeled uPA reduced FITC-uPA binding by 93% or 96%, respectively, which is remarkably close to the predicted values of 90% and 99%, respectively (Table 1). Similar results were obtained on fixed cells. The profiles obtained and the expected profiles essentially overlapped, i.e., showed log-normal distribution with essentially constant coefficient of variation, together with the expected shift of the mean values (data not shown).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 1. Flow cytometric analysis of FITC-uPA-stained cells. (A) Cells stained using a freshly thawed aliquot of FITC-uPA. (B) Cells stained using a repeatedly frozen and thawed aliquot of FITC-uPA. L/uPAR cells in B were maintained in culture for over 1 year longer than in A. Solid line; L/uPAR-expressing cells; dotted line; LC control cells.

We also tested the efficiency of staining of U937 and HT-1080, i. e., human cell lines normally expressing uPAR (Møller 1993 ). U937 showed levels of surface staining comparable to the uPAR-transfected LB6 cells (Figure 2C), and competition of FITC-uPA with unlabeled uPA confirmed the specificity of the binding observed. HT-1080 cells were also specifically stained with FITC-uPA, albeit at lower levels than U937 (data not shown).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. Flow cytometric analysis of FITC-uPA stained cells. (A,C) U937 cells. (B,D) L/uPAR cells. Cells in A and B were fixed in PFA. Cells in C and D are living cells. Solid line; FITC-uPA-stained cells; dotted line; unstained cells.

FITC-uPA efficiently stained both uPAR-transfected LB6 and U937 and HT-1080 cells fixed in 1% PFA (Figure 2A and Figure 2B). Competition of the FITC-uPA staining with unlabeled uPA confirmed the specificity of these findings (Table 1).

FITC-uPA can efficiently detect uPAR-expressing cells in fluorescence microscopy (Figure 3B). FITC-uPA staining is mostly distributed on the plasma membrane with a ring-like pattern. However, brighter spots in button-like structures are also evident, suggesting accumulation of FITC-uPA on potential cell-substrate adhesion areas (Estreicher et al. 1990 ; Møller 1993 ). Control cells incubated with equal amounts of FITC-uPA were not detectably stained (Figure 3A), confirming the specificity of the observed staining. uPA-uPAR complexes can be internalized under physiological conditions with identical kinetics in transfected murine LB6 cells and human U937 cells (Møller 1993 ). However, staining of cells with FITC-uPA on ice in the presence of 0.1% NaN3 efficiently prevents internalization of the uPA-uPAR complex (unpublished observation).



View larger version (60K):
[in this window]
[in a new window]
 
Figure 3. Fluorescence microscopic analysis of cells stained with FITC-uPA as described. (A) LC control cells; (B) L/uPAR-transfected cells. Bar = 2 µm.

FITC-uPA was stored at -80C with no adverse effects for more than 2 years. Repeated freezing and thawing of the same aliquot of FITC-uPA did not affect binding or staining efficiency, and we did not observe reduction of the apparent titer of FITC-uPA over time due to autoproteolysis. An example is shown in Figure 1A vs 1B. The essentially overlapping profiles obtained on different batches of stably transfected cells, either freshly thawed or continuously kept in culture, confirm the reproducibility of the staining procedure presented and the stability of the FITC-uPA.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

uPA and the uPAR play a crucial role in the coagulation cascade (Simon et al. 1996 ) and in the process of tumor invasion and metastasis (Mignatti and Rifkin 1993 ). Therefore, we wanted to develop a labeled uPA that could detect uPAR not only in conventional fluorescence microscopy but also in real time microscopy on living cells and in flow cytometry. uPA is a relatively large proteic ligand and binds to its cell surface receptor with high affinity. Therefore, it appeared to be a good candidate for direct conjugation to a chromophore. Other receptor ligands have been labeled with either FITC, biotin, or phycoerythrin (Hardy 1986 ; Azevedeo and Johnson 1990 ; Uriel et al. 1990 ; Bentham et al. 1993 , Bentham et al. 1994 ; De Jong et al. 1995 ). FITC had the theoretical advantage of allowing single-step labeling of uPAR and has a potentially lower steric hindrance than phycoerythrin or the biotin-avidin complex. Therefore, we tested the possibility of directly labeling huPA with FITC.

The main uPAR binding site of human uPA is between residues 12-32 (Appella et al. 1987 ). FITC binds the e-amino group of arginine and lysine residues (Hardy 1986 ), and no arginines and only one lysine (Lys23) are present in this region. Therefore, it was possible to label uPA with a sufficiently low number of FITC molecules per uPA to essentially eliminate the chances of inactivating the binding region of uPA for uPAR. uPA was conjugated with FITC using a mild procedure adapted from a FITC conjugation protocol for antibody molecules (Hardy 1986 ) that allowed us to produce FITC-uPA with an F/P close to 1.

In spite of the apparent simplicity of the production and use of labeled receptor ligands and of the theoretical advantages of their use, only relatively few of these have been produced to date (Hardy 1986 ; Azevedeo and Johnson 1990 ; Uriel et al. 1990 ; Bentham et al. 1993 , Bentham et al. 1994 ; De Jong et al. 1995 ). This probably reflects adverse effects of the labeling procedure on the ligand structure or binding efficiency. Therefore, it was crucial to prove that FITC-conjugated uPA maintained high affinity and specificity towards the uPAR. As a test system we used mouse L-cells transfected with the human uPAR. Transfectants were chosen to avoid as rigorously as possible potential staining artifacts, because the uPAR transfected vs control cells only differ in the presence of the human uPAR cDNA. This enabled us to exclude binding to other potential uPA binding sites on the cells surface, e. g., PAI-1 or plasminogen bound to their receptors (Møller 1993 ), simply by proving lack of FITC-uPA staining on the control cells. The use of mouse cells also enabled us to confirm the species specificity of the binding of FITC-uPA to uPAR (Møller 1993 ). The binding of FITC-uPA to its receptor was quantitated by flow cytometry and was confirmed by optical microscopy. The Kd of uPA for uPAR-transfectant LB6 cells is about 2-20 x 10-9 M (Appella et al. 1987 ). Therefore, nanomolar concentrations of uPA were predicted to be adequate for transfectant staining. Titration assays were performed by flow cytometry. In our hands, 28.9 nM uPA for 1 hr on ice efficiently stained 2 x 105 uPAR-transfected LB6 cells. No staining was detectable on control cells. uPAR- transfected LB6 cells express about 2.5 x 104 receptors per cell (Roldan et al. 1990 ). For comparison, tumor cells commonly show number of receptors per cell up to 3 x 105 (Roldan et al. 1990 ; Mignatti and Rifkin 1993 ). Therefore, an efficient detection of uPAR with no LB6 transfectants indicates good sensitivity of the assay. To quantitate possible adverse effects of FITC conjugation on the uPA binding affinity for uPAR, we determined the relative binding affinity of FITC-uPA in a competition assay with unlabeled uPA and proved that it is essentially unchanged compared with the native molecule.

We extended these results to human cell lines expressing the endogenous uPAR. Efficient and specific staining was obtained on the human monocytic U937 cells and on the HT-1080 ovarian carcinoma cells, albeit at lower levels, proving that FITC-uPA can detect the native human uPAR (data not shown). We also demonstrated efficient staining of PFA-fixed cells, indicating that FITC-uPA can be of potential use on histopathological samples.

FITC-uPA can efficiently detect uPAR-expressing cells in fluorescence microscopy. FITC-uPA staining is mostly distributed on the cell surface membrane with a ring-like pattern. However, brighter spots in button-like structures are also evident, suggesting accumulation of FITC-uPA on potential cell-substrate adhesion areas (Estreicher et al. 1990 ; Mignatti and Rifkin 1993 ; Møller 1993 ). Control cells incubated with equal amounts of FITC-uPA were not detectably stained, confirming the specificity of the staining observed, as did the specific displacement of FITC-uPA by unlabeled uPA.

FITC-uPA is a stable conjugate and can be used for accurate quantitative comparisons over a considerable length of time. We have stored FITC-uPA aliquots at -80C with no adverse effects for over 2 years. Repeated freezing and thawing of the same aliquot of FITC-uPA did not affect binding and staining efficiency, and we did not observe reduction of the apparent titer of FITC-uPA over time due to autoproteolysis. An example is shown in Figure 1A vs 1B. The essentially overlapping profiles obtained on different batches of stably transfected cells, either freshly thawed or continuously kept in culture, confirm the high reproducibility of the staining procedure presented and the stability of the FITC-uPA. This is also an example of use of FITC-uPA to verify the stability of expression of the uPAR on transfectants. The same transfectants were also successfully sorted for predefined levels of uPAR by flow cytometry (unpublished observation). FITC-uPA maintains its physiological proteolytic activity after binding to uPAR (data not shown). Therefore, dynamic analysis by confocal microscopy of the redistribution and proteolytic activity of the FITC-uPA-uPAR complex on binding to a substrate matrix is also allowed by the use of labeled uPA.


  Acknowledgments

Supported by the Italian Association for Cancer Research and by the Italian National Research Council, Convenzione CNR-Consorzio Mario Negri Sud, ACRO contract no. 94.01319.39, and Progetto Bilaterale contract no. 93.00870.CT04.

We thank Drs P. Mignatti and B. Donati for material and support during the course of this work.

Received for publication December 9, 1996; accepted April 18, 1997.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Alberti S, Bucci C, Fornaro M, Robotti A, Stella M (1991) Immuno-fluorescence analysis in flow cytometry: better selection of antibody-labeled cells after fluorescence overcompensation in the red channel. J Histochem Cytochem 39:701-706 [Abstract]

Alberti S, Parks DR, Herzenberg LA (1987) A single laser method for subtraction of cell autofluorescence in flow cytometry. Cytometry 8:114-119 [Medline]

Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F (1987) The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 262:4437-4440 [Abstract/Free Full Text]

Azevedeo JR, Johnson DA (1990) Temperature-dependent lateral and transverse distribution of the epidermal growth factor receptor in A431 plasma membranes. J Membr Biol 118:215-224 [Medline]

Bendayan M (1995) Possibilities of false immunocytochemical results generated by the use of monoclonal antibodies: the example of the anti-proinsulin antibody. J Histochem Cytochem 43:881-886 [Abstract/Free Full Text]

Bentham J, Aplin R, Norman MR (1994) Histochemical detection of binding sites for human growth hormone using biotinylated ligand. J Histochem Cytochem 42:103-107 [Abstract/Free Full Text]

Bentham J, Ohlsson C, Lindahl A, Isaksson O, Nilsson A (1993) A double-staining technique for detection of growth hormone and insulin-like growth factor-I binding to rat tibial epiphyseal chondrocytes. J Endocrinol 137:361-367 [Abstract]

Danø K, Andreasen PA, Grøndal-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266 [Medline]

De Jong MO, Rozemuller H, Bauman JGJ, Visser JWM (1995) Biotinylation of interleukin-2 (IL-2) for flow cytometric analysis of IL-2 receptor expression. J Immunol Methods 184:101-112 [Medline]

Dell'Arciprete R, Stella M, Fornaro M, Ciccocioppo R, Capri MG, Naglieri AM, Alberti S (1996) High-efficency expression gene cloning by flow cytometry. J Histochem Cytochem 44:629-640 [Abstract/Free Full Text]

Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Liynen HJ (1988) Urokinase plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62:531-533 [Medline]

Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme complexes. J Cell Biol 111:783-792 [Abstract]

Hardy RR (1986) Purification and coupling of fluorescent proteins for use in flow cytometry. In Weir DM, Herzenberg LA, Blackwell CC, eds. Handbook of Experimental Immunology. 104th ed. Edinburgh, Blackwell Scientific Publications, 91.1-9191.10

Hearing VJ, Law LW, Corti A, Appella E, Blasi F (1989) Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48:1270-1278 [Abstract]

Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195 [Free Full Text]

Møller LB (1993) Structure and function of the urokinase receptor. Blood Coagul Fibrinol 4:293-303 [Medline]

Nisonoff A, Hopper JE, Spring SB (1975) Nature of the active site of an antibody molecule and the mechanism of antibody-hapten interactions. In Dixon FJJ, Kunkel H, eds. The Antibody Molecule. New York, Academic Press, 43-57

Ossowski L, Clunie G, Masucci MT, Blasi F (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor invasion. J Cell Biol 115:1107-1112 [Abstract]

Ossowski L, Reich E (1983) Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611-619 [Medline]

Parks DR, Lanier LL, Herzemberg LA (1986) Flow cytometry and fluorescence activated cell sorting (FACS). In Weir DM, Herzenberg LA, Blackwell CC, eds. Handbook of Experimental Immunology. 104th ed. Edinburgh, Blackwell Scientific Publications, 29.1-2929.214

Pyke C, Kristensen P, Ralfkiaer E, Grondahl Hansen J, Eriksen J, Blasi F, Danø K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138:1059-1067 [Abstract]

Quax PHA, Pedersen N, Masucci MT, Weening-Verhoeff EJ, Danø K, Verheijen JH, Blasi F (1991) Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 2:793-803 [Medline]

Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467-474 [Abstract]

Schultz RM, Yu H, Zhang JY (1992) The role of urokinase and urokinase inhibitor in tumor cell metastasis. Fibrinolysis 6:23-29

Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA (1996) Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88:3185-3194 [Abstract/Free Full Text]

Uriel J, Lunardi-Iskandar Y, Laborda J, Torres JM, Naval J, Georgoulias V, Lowi R, Jasmin C, Mishal Z (1990) Defective uptake of alpha-fetoprotein (AFP) and transferrin (Tf) by PHA-activated peripheral blood lymphocytes from patients with AIDS and related syndromes. AIDS Res Hum Retrovir 6:401-410 [Medline]





This Article
Abstract
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Ciccocioppo, R.
Articles by Alberti, S.
Articles citing this Article
PubMed
PubMed Citation
Articles by Ciccocioppo, R.
Articles by Alberti, S.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]